Should I buy or sell Galmed Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares. View GLMD analyst ratings or view top-rated stocks .

How have GLMD shares performed in 2024?

Galmed Pharmaceuticals' stock was trading at $0.4550 at the beginning of 2024. Since then, GLMD stock has decreased by 18.3% and is now trading at $0.3716. View the best growth stocks for 2024 here .

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 39,200 shares, an increase of 532.3% from the March 15th total of 6,200 shares. Based on an average trading volume of 202,100 shares, the short-interest ratio is presently 0.2 days. Approximately 1.1% of the shares of the stock are sold short. View Galmed Pharmaceuticals' Short Interest .

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our GLMD earnings forecast .

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split on the morning of Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK) , Viking Therapeutics (VKTX) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Rite Aid (RAD) , Exelixis (EXEL) , Ocular Therapeutix (OCUL) , TG Therapeutics (TGTX) , TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP) .

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free GLMD Stock Alerts

$0.37

-0.01 (-2.62%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.37
▼
$0.38
50-Day Range: $0.30
▼
$0.42
52-Week Range: $0.26
▼
$7.80

Volume: 17,901 shs
Average Volume: 188,128 shs
Market Capitalization: $1.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Galmed Pharmaceuticals alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLMD Stock News Headlines

April 19, 2024 | americanbankingnews.com

JanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) Head-To-Head Analysis

April 16, 2024 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 13, 2024 | fool.com

Galmed Pharmaceuticals (NASDAQ: GLMD)

April 10, 2024 | investorplace.com

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

April 4, 2024 | prnewswire.com

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

March 15, 2024 | markets.businessinsider.com

Galmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver Fibrosis

March 15, 2024 | prnewswire.com

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 13, 2024 | uk.finance.yahoo.com

Galmed Pharmaceuticals Ltd (GPH.BE)

January 3, 2024 | uk.finance.yahoo.com

Galmed Pharmaceuticals Ltd. (GPH.F)

November 20, 2023 | finance.yahoo.com

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

November 4, 2023 | morningstar.com

Galmed Pharmaceuticals Ltd GLMD

September 26, 2023 | finance.yahoo.com

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

August 3, 2023 | nasdaq.com

Galmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08

July 14, 2023 | marketwatch.com

Galmed Pharma Shares Drop 30% After Public Offering Prices

July 14, 2023 | seekingalpha.com

Galmed shares slump on pricing discounted stock and warrants offering

July 14, 2023 | finance.yahoo.com

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

July 13, 2023 | investorplace.com

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?

July 10, 2023 | finance.yahoo.com

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

July 3, 2023 | bizjournals.com

Madrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drug

June 3, 2023 | benzinga.com

Galmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading Activity

June 1, 2023 | finanznachrichten.de

Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

June 1, 2023 | msn.com

Recap: Galmed Pharmaceuticals Q1 Earnings

June 1, 2023 | finance.yahoo.com

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 17, 2023 | thestreet.com

Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today

May 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)

See More Headlines

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 6/01/2023
Today: 4/19/2024
Next Earnings (Estimated): 6/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLMD
CUSIP: N/A
CIK: 1595353
Web: www.galmedpharma.com
Phone: (723) 693-8448
Fax: 972-3693-8447
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.29%
Return on Assets: -44.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.81
Quick Ratio: 4.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.75 per share
Price / Book: 0.14

Miscellaneous

Outstanding Shares: 5,050,000
Free Float: 4,046,000
Market Cap: $1.88 million
Optionable: Not Optionable
Beta: 0.87

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Allen Baharaff (Age 59)
Co-Founder, President, CEO & Chairman
Comp: $803.5k
Mr. Doron Cohen (Age 57)
Chief Financial Officer
Comp: $175.33k
Mr. Guy Nehemya (Age 39)
COO & Data Protection Officer
Comp: $235.56k
Mr. Yohai Stenzler CPA (Age 41)
Chief Accounting Officer
Comp: $239.48k
Dr. Liat Hayardeny (Age 57)
Chief Scientific Officer
Comp: $125.24k
Ms. Yael Hollander (Age 41)
Vice President of Legal Affairs & Strategy
Comp: $134.21k
Ms. Shani Ganon
Human Resources Manager
Dr. Tali Gorfine (Age 54)
Medical Consultant
Comp: $202.76k

Key Competitors

View All Competitors

GLMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares.
View GLMD analyst ratings or view top-rated stocks.
How have GLMD shares performed in 2024?: Galmed Pharmaceuticals' stock was trading at $0.4550 at the beginning of 2024. Since then, GLMD stock has decreased by 18.3% and is now trading at $0.3716.
View the best growth stocks for 2024 here.
Are investors shorting Galmed Pharmaceuticals?: Galmed Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 39,200 shares, an increase of 532.3% from the March 15th total of 6,200 shares. Based on an average trading volume of 202,100 shares, the short-interest ratio is presently 0.2 days. Approximately 1.1% of the shares of the stock are sold short.
View Galmed Pharmaceuticals' Short Interest.
When is Galmed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024.
View our GLMD earnings forecast.

How were Galmed Pharmaceuticals' earnings last quarter?: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.41.
When did Galmed Pharmaceuticals' stock split?: Galmed Pharmaceuticals's stock reverse split on the morning of Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Galmed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).
How do I buy shares of Galmed Pharmaceuticals?: Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

GLMD Stock Price History

GLMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GLMD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info